{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"The Closing Bell Featuring Sigyn Therapeutics - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"2v47mdbR2K\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-closing-bell-featuring-sigyn-therapeutics\/\">The Closing Bell Featuring Sigyn Therapeutics<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/the-closing-bell-featuring-sigyn-therapeutics\/embed\/#?secret=2v47mdbR2K\" width=\"600\" height=\"338\" title=\"&#8220;The Closing Bell Featuring Sigyn Therapeutics&#8221; &#8212; Market Newsdesk\" data-secret=\"2v47mdbR2K\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"The Interactive Videoconference Occurs Today at 4pm Eastern \/ 1pm Pacific Time SAN DIEGO, April 21, 2021 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome, announces that its Chairman and CEO, Jim Joyce, will be featured on the Closing Bell videoconference hosted by Force Family Offices at 4pm Eastern today.\u00a0 This interactive event provides investors with an opportunity to talk directly with Mr. Joyce regarding the advancement of Sigyn Therapy\u2122, a novel blood purification technology designed to treat sepsis and other life-threatening conditions that are induced by cytokine storm syndrome.\u00a0 Also participating in the event will be analyst Rob Goldman &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyMDY5NiM0MTMxMjA0IzUwMDAzMjA5OA=="}